Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 11/20 | 0.51 |
| ▸ | CASP6 | P55212 | 9/20 | 0.51 |
| ▸ | CASP8 | Q14790 | 9/20 | 0.51 |
| ▸ | CASP1 | P29466 | 8/20 | 0.50 |
| ▸ | KLK7 | P49862 | 1/20 | 0.46 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL78880 | 1.00 | CASP3 (0.51) | CASP3CASP6CASP8CASP1KLK7 | |
| SCHEMBL17261859 | 0.93 | CASP3 (0.59) | CASP3CASP6CASP8 | |
| SCHEMBL22862226 | 0.93 | KLK7 (0.54) | CASP3CASP6CASP8CASP1KLK7 | |
| SCHEMBL4425707 | 0.92 | CASP3 (0.60) | CASP3CASP6CASP8 | |
| SCHEMBL10073348 | 0.92 | CASP3 (0.60) | CASP3CASP6CASP8 | |
| SCHEMBL626915 | 0.92 | CASP3 (0.60) | CASP3CASP6CASP8 | |
| SCHEMBL26623260 | 0.87 | CASP1 (0.62) | CASP3CASP6CASP8CASP1 | |
| SCHEMBL26623257 | 0.87 | CASP1 (0.62) | CASP3CASP6CASP8CASP1 | |
| SCHEMBL20980797 | 0.87 | CASP3 (0.53) | CASP3CASP6CASP8CASP1 | |
| SCHEMBL22404667 | 0.85 | KLK7 (0.47) | CASP3CASP6CASP8CASP1KLK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129381-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-06 | — | — | US | disclosed |
| US-8071618-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-12-06 | — | — | US | disclosed |
| US-7923433-B2 | Activity-based probes and methods of their preparation and use | ACTIVX BIOSCIENCES, INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-20100137359-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-03 | — | — | US | disclosed |
| US-20090281128-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-12 | — | — | US | disclosed |
| US-7612091-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-03 | — | — | US | disclosed |
| US-7553852-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-06-30 | — | — | US | disclosed |
| EP-1583726-A4 | ACTIVITY-BASED PROBES, AND METHODS OF THEIR PREPARATION AND USE | ACTIVX BIOSCIENCES INC (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20070141624-A1 | ACTIVITY-BASED PROBES AND METHODS OF THEIR PREPARATION ANS USE | ACTIVX BIOSCIENCES, INC. | 2007-06-21 | — | — | US | disclosed |
| EP-1583726-A2 | ACTIVITY-BASED PROBES, AND METHODS OF THEIR PREPARATION AND USE | Activx Biosciences, Inc. (US) | 2005-10-12 | — | — | EP | disclosed |
| EP-1581501-A1 | 4-OXO-3-(1-OXO-1H-ISOQUINOLIN-2-YLACETYLAMINO)-PENTANOIC ACID ESTER AND AMIDE DERIVATIVES AND THEIR USE AS CASPASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2005-10-05 | — | — | EP | disclosed |
| EP-1539701-A1 | CASPASE INHIBITORS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040192612-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2004-09-30 | — | — | US | disclosed |
| WO-2004058718-A1 | 4-OXO-3-(1-OXO-1H-ISOQUINOLIN-2-YLACETYLAMINO)-PENTANOIC ACID ESTER AND AMIDE DERIVATIVES AND THEIR USE AS CASPASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004033397-A2 | ACTIVITY-BASED PROBES, AND METHODS OF THEIR PREPARATION AND USE | ACTIVX BIOSCIENCES, INC. (US) | 2004-04-22 | — | — | WO | disclosed |
| US-20040072850-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2004-04-15 | — | — | US | disclosed |
| WO-2004002961-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137359-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP3, CASP1, CASP5 | CASP3 1/4885CASP6 5/4885CASP8 10/4885 |
| US-20040072850-A1 | Caspase inhibitors and uses thereof | CASP1, CASP5, CASP2 | CASP3 4/4885CASP6 8/4885CASP8 10/4885 |
| US-20070141624-A1 | ACTIVITY-BASED PROBES AND METHODS OF THEIR PREPARATION ANS USE | DNPEP, CTRL, ARSA | CASP3 2191/4885CASP6 1002/4885CASP8 2473/4885 |
| US-20040192612-A1 | Caspase inhibitors and uses thereof | CASP1, CASP3, CASP5 | CASP3 2/4885CASP6 5/4885CASP8 12/4885 |
| US-20090281128-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP5, CASP3 | CASP3 3/4885CASP6 7/4885CASP8 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.